^
Association details:
| Biomarker: | EGFR T790M |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Nerlynx (neratinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) + gedatolisib (PF-05212384) (mTOR inhibitor, PI3K inhibitor, mTORC1 inhibitor, mTORC2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor
Excerpt:
...used H1975 that has L858R and T790M mutant EGFR...Exposure (24 hours) of H1975 to combined PKI-587 and HKI-272 (250 nmol/L) markedly increased suppression of p-Akt (T308; IC50 < 30 nmol/L), increased caspase 3/7 activity (Supplementary Fig. 5C), and induced cPARP at 30 nmol/L or more...When PKI-587 (5 mg/kg, d×5 once) was given in combination with HKI-272 (40 mg/kg, po daily) significantly (P < 0.02), more antitumor effect than either compound given alone was observed in a 14-day study...
DOI:
10.1158/1078-0432.CCR-10-1694
